Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism
Kenvue sank 15% Friday after a Wall Street Journal report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.
Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spinout, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.
The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking over-the-counter meds.
The report is also expected to float a folate-derived therapy as a potential treatment.
Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.
Kenvue shares are now down over 18% year to date.
The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking over-the-counter meds.
The report is also expected to float a folate-derived therapy as a potential treatment.
Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.
Kenvue shares are now down over 18% year to date.
